Latest News
argenx SE
- Argenx confirmatory trial update for Vyvgart puts small dent in strong Q3
- Jefferies reiterates argenx stock Buy rating after Q3 beat By Investing.com
- argenx Q3 2026 slides: 54% growth fuels 5 potential 2027 launches
- Argenx Vyvgart Sales Surge 54% in Q3 Amid Forte Acquisition
- What’s next for argenx, Europe’s autoimmune breakthrough?
- argenx Meets Primary Endpoint in Phase II Celiac Disease Study
- Argenx Shares Plunge After Autoimmune-Disease Trial Halt
- Argenx walks away from Vyvgart Sjögren's disease trial after futility flag
- Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
- Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
- Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail
- Vyvgart’s expanding pipeline supports argenx’s long-term sales potential
Headlines from the last 30 days, linking to the original publishers. See all market news →